| Business Summary | | Schering-Plough
Corporation,
a
worldwide
research-based
pharmaceutical
company,
and
its
subsidiaries
are
engaged
in
the
discovery,
development,
manufacturing
and
marketing
of
pharmaceutical
products.
Although
discovery
and
development
efforts
target
the
field
of
human
health,
application
in
the
field
of
animal
health
can
result
from
these
efforts.
The
Company
operates
primarily
in
the
prescription
pharmaceutical
marketplace.
However,
where
appropriate,
the
Company
has
sought
regulatory
approval
to
switch
prescription
products
to
over-the-counter
(OTC)
status
as
a
means
of
extending
a
product's
life
cycle.
In
this
way,
the
OTC
marketplace
is
yet
another
means
of
maximizing
the
return
on
investments
in
discovery
and
development. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | SGP
is
engaged
in
the
discovery,
development,
manufacturing
and
marketing
of
pharmaceutical
and
health
care
products
worldwide,
including
prescription
drugs,
animal
health,
over-the-counter,
foot
care
and
sun
care
products.
For
the
six
months
ended
6/30/01,
revenues
fell
1%
to
$4.95
billion.
Net
income
fell
5%
to
$1.2
billion.
Results
reflect
foreign
exchange
rate
fluctuations,
lower
sales
of
LOTRISONE
and
increased
costs
related
to
manufacturing
issues. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Richard Kogan, 59 Chairman,
CEO, Director | $9.9M | $11.6M | Jack Wyszomierski, 45 Exec.
VP, CFO | 2.5M | 6.9M | Joseph Connors, 52 Exec.
VP, Gen. Counsel | 2.6M | 4.9M | John Ryan, 60 Sr.
VP/Director of HR | -- | -- | Geraldine Foster, 57 Sr.
VP of Investor Relations and Corp. Communications | -- | -- | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|